Livforsakringsbolaget Skandia, Omsesidigt Halozyme Therapeutics, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.22 Billion
- Q2 2024
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 46,100 shares of HALO stock, worth $2.73 Million. This represents 0.2% of its overall portfolio holdings.
Number of Shares
46,100
Previous 5,300
769.81%
Holding current value
$2.73 Million
Previous $215,000
1022.33%
% of portfolio
0.2%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
487Shares Held
123MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1.04 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$762 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$344 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$239 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$220 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...